Phase 1 and Phase 2 are now complete. Topical WST-057 (Pirenzepine was shown to be safe and tolerable when administered to diabetic peripheral neuropathy patients for up to six months in these studies, but will need to be studied in a larger Phase 3 population (several thousand). (per Winsantor's site) In parallel, we are preparing studies in other indications, such as chemo-induced peripheral neuropathy. (per Winsator's site) It is a topical cream.